Notice2021-17011
Prospective Grant of an Exclusive Patent License: Multi-Domain Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients With Atherosclerotic Cardiovascular Disease, Including Patients Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney Injury
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 10, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Phyxius Therapeutics, Inc., a start-up company incorporated as a C corporation under the laws of the state of Delaware, to practice the inventions covered by the patent estate listed in the Supplementary Information section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 151 (Tuesday, August 10, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 151 (Tuesday, August 10, 2021)]
[Notices]
[Pages 43670-43671]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-17011]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Multi-Domain
Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients
With Atherosclerotic Cardiovascular Disease, Including Patients
Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney
Injury
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung, and Blood Institute, an institute of
the National Institutes of Health, Department of Health and Human
Services, is contemplating the grant of an exclusive patent license to
Phyxius Therapeutics, Inc., a start-up company incorporated as a C
corporation under the laws of the state of Delaware, to practice the
inventions covered by the patent estate listed in the Supplementary
Information section of this notice. This is a first notice intended to
apprise the public of a change in prospective licensee of the subject
intellectual property rights in the stated field of use.
DATES: Only written comments and/or applications for a license which
are received by the National Heart, Lung, and Blood Institute on or
before August 25, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an exclusive patent license
should be directed to: Michael Davis, J.D., Ph.D., Senior Technology
Transfer Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD
20892-2479, phone number 301-451-9032, or <a href="/cdn-cgi/l/email-protection#99f4f0faf1f8fcf5b7fdf8eff0eaadd9f7f0f1b7fef6ef"><span class="__cf_email__" data-cfemail="214c48424940444d0f454057485215614f48490f464e57">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Intellectual Property
----------------------------------------------------------------------------------------------------------------
Patent
NIH REF No. Title Application Filing Date Issued Patent Issue Date
No. No.
----------------------------------------------------------------------------------------------------------------
E-114-2004-0-US-01............ Multi-Domain 60/619,392 10/15/04 .............. ..............
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-PCT-02........... Multi-Domain PCT/US2005/ 10/14/05 .............. ..............
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-AU-03............ Multi-Domain 2005295640 10/14/05 2005295640 11/10/11
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-CA-04............ Multi-Domain 2584048 10/14/05 2584048 08/09/16
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-EP-05............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-JP-06............ Multi-Domain 2007-536912 10/14/05 5,091,679 09/21/12
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-US-07............ Multi-Domain 11/577,259 04/13/07 7,572,771 08/11/09
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-US-08............ Multi-Domain 12/497,443 07/02/09 8,071,746 12/06/11
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-US-09............ Multi-Domain 12/766,761 04/23/10 8,148,323 04/03/12
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-CH-11............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-DE-12............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-ES-13............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-FR-14............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-GB-15............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-IT-16............ Multi-Domain 05815961.7 10/14/05 1812474 05/26/10
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
E-114-2004-0-US-17............ Multi-Domain 13/407,132 02/28/12 8,835,378 09/16/14
Amphipathic
Helical
Peptides And
Methods Of
Their Use.
----------------------------------------------------------------------------------------------------------------
All U.S. and foreign patents and applications claiming priority to
any member of the above.
The patent rights in these inventions have been assigned or
exclusively licensed to the Government of the United States of America.
The prospective exclusive license territory may be worldwide and in
fields of use that may be limited to use as a human therapeutic in
patients with atherosclerotic cardiovascular disease (ASCVD), including
patients undergoing cardiovascular surgery who are at risk of acute
kidney injury.
The patents listed above cover an invention directed to peptides or
[[Page 43671]]
peptide analogs with multiple amphipathic alpha helical domains that
promote lipid efflux from cells via an ABCA1-dependent pathway. This
invention is also directed to methods of identifying non-cytotoxic
peptides that promote ABCA1-dependent lipid efflux from cells, and to
methods of using multi-domain amphipathic alpha helical peptides or
peptide analogs to treat or inhibit dyslipidemic disorders.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing.
The prospective exclusive license may be granted unless within fifteen
(15) days from the date of this published notice, the National Heart,
Lung, and Blood Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute.
[FR Doc. 2021-17011 Filed 8-9-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 10, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.